Recursion Pharmaceuticals Inc(RXRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 5:09 PM ET (Korea 10/28 06:09)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.04 | Insider Own | 10.21% | Shs Outstand | 597.8M | Perf Week | 10.66% |
| Market Cap | 2.42B | Forward P/E | - | EPS next Y | 3% | Insider Trans | -0.67% | Shs Float | 536.8M | Perf Month | 9.46% |
| Enterprise Value | 1.94B | PEG | - | EPS next Q | -0.22 | Inst Own | 55.91% | Short Float | 30.17% | Perf Quarter | 36.36% |
| Income | -0.52B | P/S | 44.14 | EPS this Y | 37.51% | Inst Trans | 4.19% | Short Ratio | 7.45 | Perf Half Y | 18.77% |
| Sales | 0.05B | P/B | 2.36 | EPS next 5Y | 20.14% | ROA | -41.26% | Short Interest | 161.93M | Perf YTD | -0.98% |
| Book/sh | 1.71 | P/C | 4.39 | EPS past 3/5Y | -1.84% -22.39% | ROE | -56.58% | 52W High | -37.69% ($6.50) | Perf Year | -35.71% |
| Cash/sh | 0.92 | P/FCF | - | Sales past 3/5Y | 23.3% 79.91% | ROIC | -54.11% | 52W Low | 46.21% ($2.77) | Perf 3Y | -23.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 41.98% | Gross Margin | -88.39% | Volatility(W/M) | 6.05% 10.16% | Perf 5Y | -78.51% |
| Dividend TTM | - | EV/Sales | 35.31 | Sales Y/Y TTM | -15.08% | Oper. Margin | -991.72% | ATR (14) | 0.34 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.03 | EPS Q/Q | 40.28% | Profit Margin | -945.92% | RSI (14) | 54.44 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.03 | Sales Q/Q | -60.1% | SMA20 | 1.81% ($3.98) | Beta | 1.15 | Target Price | $7.32 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/11/2 | SMA50 | 9.72% ($3.69) | Rel Volume | 1.01 | Prev Close | $3.8 |
| Employees | 600 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | -4.17% -33.42% | SMA200 | 14.55% ($3.54) | Avg Volume(3M) | 21.73M | Price | $4.05 |
| IPO | 2021/4/16 | Option/Short | Yes/Yes | Trades | 32438 | Volume | 22,022,968 | Change | 6.58% |
A U.S. biotech company operating an AI-based drug discovery platform. It combines artificial intelligence with automated biology experiments in a large-scale, data-driven platform to identify and develop new drug candidates, with a pipeline spanning multiple areas including oncology and rare diseases. The company stands out in biotech by integrating its AI drug discovery platform with its development pipeline.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
Next earnings report: November 2
6 days to go.
RXRX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,414. Peers typically go for $1,213.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -78.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
30.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #83 of 594 in the industry
Based on market cap of $2B.
ADMA#80 Adma Biologics Inc $3B PER 15.9 
SLS#81 SELLAS Life Sciences Group Inc $2B PER - 
NAMS#82 NewAmsterdam Pharma Company NV $2B PER - RXRX#83 Recursion Pharmaceuticals Inc $2B PER - 
CLDX#84 Celldex Therapeutics Inc $2B PER - 
FAQ
What kind of company is RXRX?
RXRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RXRX?
The market cap of RXRX is approximately $2.4B, ranking 1,912 within its sector.
What is the 52-week high and low for RXRX?
RXRX has recorded a 52-week high of $6.50 and a low of $2.77.
